Adjusting Medicare Drug Price Negotiation Rules for Rare Disease Treatments.
This bill modifies how Medicare negotiates the price of certain drugs used exclusively for rare diseases (orphan drugs). It raises a specific financial threshold used in the formula for calculating the maximum fair price from $200 million to $400 million. This adjustment aims to refine price control mechanisms for specialized, high-cost therapies, impacting drug costs for Medicare beneficiaries starting in 2028.
Key points
Changes the rules for negotiating drug prices under the Medicare program, specifically targeting drugs approved only for rare diseases.
Increases a key financial threshold used in the maximum drug price calculation from $200 million to $400 million.
These changes take effect starting January 1, 2028, affecting drug costs for Medicare recipients.
Introduced
Citizen Poll